Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc Announces Statement On FDA Advisory Committee Meeting About Sugammadex Sodium Injection


Tuesday, 16 Jul 2013 11:57am EDT 

Merck & Co Inc announced that U.S. Food and Drug Administration (FDA) has cancelled Thursday's discussion of sugammadex at the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium injection is Merck's investigational medicine for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. The FDA advised Merck that the agency needs additional time to assess the results of the FDA's recently completed inspection of a clinical trial site. The site was one of four sites that conducted the hypersensitivity study previously requested by the agency. Merck is engaged in discussions with the FDA to identify the steps necessary to enable the agency to complete its review. 

Company Quote

59.88
-0.11 -0.18%
4:01pm EDT